Insights On Drug Development

  1. How The Accelerator™ Drug Development Model Enhances eNPV 2/25/2026

    Discover how an integrated CDMO and CRO model can accelerate development timelines, add up to $62.9 million in value, and help you maximize long-term pipeline success with a single, streamlined partner.

  2. Concept To Market: Scaling And Manufacturing Semi-Solid Topical Drugs 2/23/2026

    Learn how formulation, processing, and scale‑up choices impact the stability, structure, and performance of semi‑solid topicals while ensuring consistent quality through development.

  3. How Confident Are You In Your Autoinjector? 2/23/2026

    As demand for self-administered therapies accelerates, autoinjectors, formally known as automated needle-based injection systems (NIS-AUTO), are playing a central role in modern medicine. 

  4. A Patented Process For Intermediates Useful For Upadacitinib 2/18/2026

    Discover how innovative and safer synthetic strategies can streamline the manufacture of Upadacitinib while addressing the complexity and safety challenges inherent in its key intermediates.

  5. Corticosteroids And Hormonal Therapies — History, Use, And Future Outlook 2/18/2026

    Explore how evolving science, expanding global demand, and next-generation innovations are reshaping the future of corticosteroid and hormonal therapies — and what this transformation means for the years ahead.

  6. Redefining OSD Development Through Foresight And Innovation 2/12/2026

    From early formulation challenges to scale-up and commercial readiness, proactive planning and integrated capabilities help teams anticipate risks, accelerate decision-making, and maintain momentum across development.

  7. FIH: Reach Milestones Sooner With A Technology-Driven Approach 2/12/2026

    Accelerate your path to IND and FiH with AI-driven design, advanced cell line engineering, and intensified processes delivering high titers in 9–14 months.

  8. CHO K1 Cell Culture Process Intensification For Enhanced Production Of IgG mAbs 2/12/2026

    Discover how our optimized CHO K1 cell lines achieved up to an 80% increase in titer while maintaining product quality through molecule-specific process development strategies.

  9. The Science Of Cell Line Development For Biologics 2/12/2026

    Selecting and engineering the right cell line is not simply a technical milestone; it is a strategic decision that shapes cost of goods, development timelines, and the overall probability of success.

  10. Right From The Start: Smarter Developability For Stronger Formulations 2/4/2026

    Early developability assessment integrates manufacturability, QbD, flexible formulations, and CDMO support to cut risk, speed development, and enable scalable, robust drugs.